All In Biotech

Free tool

FAERS Monitor: Xyosted (Autoinjector)

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209863 or its brand name (Xyosted (Autoinjector), Testosterone Enanthate). Reports on generic versions are filed under their own applications.

Reports

1,642

Serious

475

29% of reports

Hospitalization

255

Death reported

27

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product dose omission issue354
  • injection site pain160
  • injection site haemorrhage142
  • drug ineffective111
  • off label use100
  • injection site mass61
  • fatigue57
  • injection site bruising56
  • accidental exposure to product53
  • product dose omission52
  • product use in unapproved indication51
  • injection site erythema41
  • product use issue39
  • injury associated with device34
  • drug abuse33

Reports by year received

View as table
YearReports
20042
20056
20065
20077
200810
200917
201010
20116
201215
201316
201425
201555
201639
201726
201831
201980
2020198
2021205
2022212
2023240
202453
2025242
2026142

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,517 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
injection site haemorrhageSignal14222.819.52,946
injury associated with deviceSignal3421.415.4641
injection site massSignal6121.216.51,152
product dose omission issueSignal35415.414.14,827
product dose omissionSignal5210.27.8424
injection site bruisingSignal569.07.0391
injection site painSignal1606.75.8779
accidental exposure to productSignal536.65.1247
drug abuseSignal335.13.6104
injection site erythemaSignal414.23.199
product use issueSignal392.71.939
product use in unapproved indicationSignal512.62.051
off label use1001.51.215
drug ineffective1111.10.91
fatigue570.90.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.